Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Disease of Mucosa

Abstract

An immunomodulatory compound is utilized to treat mucosa disease.

1 - 16 . (canceled) 
     
     
         17 . A method for reducing the amount of mucosal deterioration, injury, or damage to at least one of oral and esophageal mucosal tissues, the mucosal deterioration, injury, or damage resulting from radiation treatment in a subject undergoing radiation therapy for head and neck cancer, the method comprising: administering to said subject an effective amount of a compound of the formula 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein: n is 1 or 2; R is hydrogen or a C2-10 acyl or C1-6 alkyl; and X is L-tryptophan or D-tryptophan. 
       
     
     
         18 . The method of  claim 17 , wherein said compound is not γ-D-glutamyl-L-tryptophan (SCV-07) or a pharmaceutically acceptable salt thereof. 
     
     
         19 . The method of  claim 17 , wherein the oral and/or esophageal mucosal deterioration, injury, or damage comprises ulcerative lesions. 
     
     
         20 . The method of  claim 17 , wherein said radiation is administered at a cumulative dose of at least about 15 Gy. 
     
     
         21 . The method of  claim 17 , wherein said radiation is administered at a cumulative dose of at least about 40 Gy. 
     
     
         22 . The method of  claim 17 , wherein said radiation is administered at a cumulative dose of at least about 60 Gy. 
     
     
         23 . The method of  claim 17 , wherein a chemotherapy is administered to the subject. 
     
     
         24 . The method of  claim 23 , wherein the chemotherapy is cis-platin. 
     
     
         25 . The method of  claim 24 , wherein said cis-platin is administered at a dosage within a range of 0.1-50 mg/kg. 
     
     
         26 . The method of  claim 24 , wherein said cis-platin is administered at a dosage of about 5 mg/kg. 
     
     
         27 . The method of  claim 17  wherein said compound or a pharmaceutically acceptable salt thereof is administered before radiation exposure. 
     
     
         28 . The method of  claim 17  wherein said compound or a pharmaceutically acceptable salt thereof is administered during radiation exposure. 
     
     
         29 . The method of  claim 17  wherein said compound or a pharmaceutically acceptable salt thereof is administered after radiation exposure. 
     
     
         30 . The method of  claim 17  wherein said compound or a pharmaceutically acceptable salt thereof is administered before administration of 7-8 Gy of radiation.